secwatch.observer — SEC 8-K summary
======================================

Issuer:     IRADIMED CORP (IRMD)
CIK:        0001325618
Form:       8-K
Filed at:   2022-02-04T23:59:59+00:00
Accession:  0001104659-22-011698
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Q4 revenue up 39% YoY to $11.9M; guides FY22 rev $51.4-52.2M
------------------------------------------------------------

- Q4 2021 GAAP diluted EPS $0.31 vs $0.05 YoY; non-GAAP diluted EPS $0.33 vs $0.07.
- Full-year 2021 revenue $41.8M (+32% YoY); full-year GAAP EPS $0.74 vs $0.11.
- Gross profit margin improved to 77.9% in Q4 vs 75.3% YoY; free cash flow $10.8M for FY.
- FY2022 guidance: revenue $51.4M-$52.2M, GAAP EPS $0.82-$0.90; Q1 rev $12.1M-$12.3M.
- Record bookings growth: Q4 bookings +48% YoY, FY bookings +39% YoY, signaling strong demand.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1325618/000110465922011698/0001104659-22-011698-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1325618/000110465922011698/tm225491d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-011698

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer